Meet the Investors  


Kjell Mortier | Fund Manager | Novalis Biotech Acceleration Fund

Prior to working for Novalis Biotech Incubation, Dr. Kjell Mortier acquired approximately 20 years of experience in the biotech industry working in various scientific roles. At Ablynx, now part of Sanofi, he was responsible for the bioanalytical and immunogenicity part of dedicated clinical programs. At Eurofins, a leading CRO in the pharma, food and environmental industry, he supported the CMC-analytical part for various customers in the pharma industry. Kjell also obtained certification for financial analysis at EHSAL Management School.


About Novalis Biotech Acceleration Fund

(Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionize healthcare. The fund’s core competence lies in digitalization in the life sciences with a focus on “enabling technologies” within research and manufacturing technologies, genomics, bioinformatics, diagnostics, and personalized medicine.

Powered by:
Hyphen Projects   

    Connect     

Join Global Investor Forum

Privacy Policy
Terms & Conditions 
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01
         
 
 

                                    

          Register here
 
© Copyright 2023 by Hyphen Projects